$6.99
-0.40 (-5.41%)
Open$7.35
Previous Close$7.39
Day High$7.56
Day Low$6.97
52W High$17.43
52W Low$5.06
Volume—
Avg Volume200.0K
Market Cap111.01M
P/E Ratio—
EPS$-4.20
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
+253.2% upside
Current
$6.99
$6.99
Target
$24.69
$24.69
$14.59
$24.69 avg
$25.91
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.96M | 11.88M | 13.51M |
| Net Income | 575.0K | 486.8K | 473.9K |
| Profit Margin | 4.4% | 4.1% | 3.5% |
| EBITDA | 905.5K | 814.6K | 969.2K |
| Free Cash Flow | 454.1K | 555.8K | 696.0K |
| Rev Growth | -0.8% | +15.7% | +3.2% |
| Debt/Equity | 0.71 | 1.01 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $286.20 | +0.94% | 48.5 | 501.19B |
| AMGN | Amgen Inc | $435.64 | -0.72% | 25.1 | 236.00B |
| GILD | Gilead Sciences Inc | $166.43 | -0.06% | — | 208.61B |
| VRTX | Vertex Pharmaceuticals Inc | $515.02 | -1.08% | 32.6 | 129.77B |
| REGN | Regeneron Pharmaceuticals | $920.69 | -0.29% | 19.8 | 95.40B |
| ALNY | Alnylam Pharmaceuticals Inc | $143.82 | -2.71% | 7.3 | 19.80B |